These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24897555)

  • 1. Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo.
    Ashley JD; Stefanick JF; Schroeder VA; Suckow MA; Kiziltepe T; Bilgicer B
    J Med Chem; 2014 Jun; 57(12):5282-92. PubMed ID: 24897555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo.
    Ashley JD; Stefanick JF; Schroeder VA; Suckow MA; Alves NJ; Suzuki R; Kikuchi S; Hideshima T; Anderson KC; Kiziltepe T; Bilgicer B
    J Control Release; 2014 Dec; 196():113-21. PubMed ID: 25312543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical and biological evaluation of dipeptidyl boronic acid proteasome inhibitors for use in prodrugs and pro-soft drugs targeting solid tumors.
    Milo LJ; Lai JH; Wu W; Liu Y; Maw H; Li Y; Jin Z; Shu Y; Poplawski SE; Wu Y; Sanford DG; Sudmeier JL; Bachovchin WW
    J Med Chem; 2011 Jul; 54(13):4365-77. PubMed ID: 21634429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibition: novel therapy for multiple myeloma.
    Kaufman JL; Lonial S
    Onkologie; 2006 Apr; 29(4):162-8. PubMed ID: 16601373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
    Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
    Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
    Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM
    Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.
    Loi M; Becherini P; Emionite L; Giacomini A; Cossu I; Destefanis E; Brignole C; Di Paolo D; Piaggio F; Perri P; Cilli M; Pastorino F; Ponzoni M
    J Control Release; 2014 Oct; 192():157-66. PubMed ID: 25041999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib as an antitumor agent.
    Roccaro AM; Hideshima T; Richardson PG; Russo D; Ribatti D; Vacca A; Dammacco F; Anderson KC
    Curr Pharm Biotechnol; 2006 Dec; 7(6):441-8. PubMed ID: 17168660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells.
    Wang X; Feng X; Wang J; Shao N; Ji C; Ma D; Henter JI; Fadeel B; Zheng C
    Anticancer Drugs; 2014 Mar; 25(3):282-8. PubMed ID: 24300915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.
    Suzuki R; Hideshima T; Mimura N; Minami J; Ohguchi H; Kikuchi S; Yoshida Y; Gorgun G; Cirstea D; Cottini F; Jakubikova J; Tai YT; Chauhan D; Richardson PG; Munshi NC; Utsugi T; Anderson KC
    Leukemia; 2015 Feb; 29(2):510-4. PubMed ID: 25306900
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting the proteasome as a therapeutic strategy against haematological malignancies.
    Orlowski RZ; Zeger EL
    Expert Opin Investig Drugs; 2006 Feb; 15(2):117-30. PubMed ID: 16433592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
    Tobinai K
    Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092
    [No Abstract]   [Full Text] [Related]  

  • 14. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
    Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of bortezomib in the treatment of multiple myeloma].
    Gotoh A; Ohyashiki K
    Nihon Rinsho; 2007 Dec; 65(12):2309-14. PubMed ID: 18069278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.
    Groll M; Berkers CR; Ploegh HL; Ovaa H
    Structure; 2006 Mar; 14(3):451-6. PubMed ID: 16531229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
    Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
    J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.
    Moreau P; Coiteux V; Hulin C; Leleu X; van de Velde H; Acharya M; Harousseau JL
    Haematologica; 2008 Dec; 93(12):1908-11. PubMed ID: 18768528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
    Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Classification and synthesis of ubiquitin-proteasome inhibitor].
    Li J; Zhang DY; Wu XM
    Yao Xue Xue Bao; 2009 Dec; 44(12):1313-9. PubMed ID: 21351462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.